Company:  ATARA BIOTHERAPEUTICS, IN ... (ATRA)
Form Type:  424B5
Filing Date:  1/4/2018 
CIK:  0001604464 
Address:  611 GATEWAY BLVD
SUITE 900
 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  650-278-8930 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$29.50  
Change: 
2.00 (7.27%)  
Trade Time: 
Jan 19  
Market Cap: 
$1.11B
Trade ATRA now with 

© 2018  
Description of Business
We are a clinical-stage biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation. We are focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. Cytotoxic T-cells, otherwise known as cytotoxic T lymphocytes, or CTLs, can mount an immune response against an antigen or antigens in order to combat viral infection or disease. Our cellular therapy platform is designed to provide a healthy immune capability to a patient whose immune system is compromised or is unable to identify the disease targets. Our product candidates are derived from cells donated by healthy individuals. These cells are trained to recognize an antigen, expanded, characterized, banked and held as inventory.
Register and access this filing in:     
  FORM 424B5
    Dilution
    U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, ...
    Underwriting
    Experts
    TABLE OF CONTENTS
      INCOME STATEMENT
    ABOUT THIS PROSPECTUS
    Use of Proceeds
    RISK FACTORS
    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
    USE OF PROCEEDS
    RATIO OF EARNINGS TO FIXED CHARGES
    DESCRIPTION OF CAPITAL STOCK
    Transfer Agent and Registrar
    DESCRIPTION OF DEBT SECURITIES
    DESCRIPTION OF WARRANTS
    PLAN OF DISTRIBUTION
    LEGAL MATTERS
    WHERE YOU CAN FIND MORE INFORMATION